两个主要的癌症生物标志物作为双酶抗瘤活动的分子标
Elena Dudkina1, Vera Ulyanova1, Violetta Asmandiyarova1
1Department of Microbiology, Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan 420008, Russia.
来自Bacillus pumilus (双酶) 的核糖酶通过直接向EGFR和RAS瘤基因来抑制致癌的MAPK信号传递. 这种多目标方法为克服癌症治疗中的耐药性提供了一个有希望的策略.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 癌症经常涉及失调的信号通路,特别是基因激活蛋白激酶 (MAPK) 级联,在超过85%的癌症中被激活.
- 诸如EGFR (表皮生长因子受体) 和RAS瘤基因等关键组件的遗传改变驱动MAPK通路的过活化,这对细胞命运至关重要.
- 尽管它们很重要,但针对EGFR和RAS的有效向疗法仍然难以捉摸.
研究的目的:
- 为了研究来自虫杆菌 (Bacillus pumilus) 的核糖核酶 (核糖核酶) 作为抗癌剂的潜力.
- 阐明双酶影响MAPK信号的机制及其与EGFR和RAS的相互作用.
- 评估binase在癌症治疗中克服治疗耐药性的潜力.
主要方法:
- 双酶,EGFR和RAS蛋白之间的直接相互作用研究.
- 评估双酶对MAPK信号通路活动的影响.
- 评估binase的抗瘤潜力及其对药物耐药性发展的影响.
主要成果:
- 双酶直接与EGFR和RAS蛋白相互作用,抑制MAPK信号传递.
- 这种抑制有助于比纳所观察到的抗瘤作用,补充其酶活性.
- 双酶的多目标性质证明了防止药物耐药性的出现的潜力.
结论:
- 比纳斯作为一种新的抗癌疗法具有显著的潜力,因为它同时向关键的癌基因EGFR和RAS.
- 双酶直接抑制MAPK信号传递提供了一种新的策略,以对抗由这些变化驱动的癌症.
- 比纳斯的多目标能力对于克服药物耐药性至关重要,这是当前癌症治疗的主要挑战.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mitogens and the Cell Cycle
